Literature DB >> 22177159

Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer.

Jairam R Eswara1, Jason A Efstathiou, Niall M Heney, Jonathan Paly, Donald S Kaufman, W Scott McDougal, Francis McGovern, William U Shipley.   

Abstract

PURPOSE: Radical cystectomy has been the standard treatment for muscle invasive bladder cancer. Combined modality therapy involving transurethral bladder tumor resection, external beam radiation and chemotherapy is an effective alternative to cystectomy in selected patients. Salvage cystectomy is reserved for those in whom combined modality therapy fails. We characterized complications associated with salvage cystectomy.
MATERIALS AND METHODS: From 1986 to 2007 of 348 patients undergoing bladder sparing therapy 102 (29%) underwent salvage cystectomy, 91 of whom were treated at Massachusetts General Hospital after receiving combined modality therapy for T2-T4aNxM0 bladder cancer. Patients underwent transurethral bladder tumor resection followed by chemoradiation (40 Gy). Early assessment was performed by cystoscopy/re-biopsy. Patients with complete response continued with consolidation chemoradiation (total dose 64 Gy). Immediate salvage cystectomy (50 of 91) was performed for persistent disease, while delayed salvage cystectomy (41 of 91) was performed for an invasive recurrence. Complications were classified using the Clavien system.
RESULTS: Median patient age was 69.4 years (range 27.5 to 88.9) and median living patient followup was 12 years (range 0 to 23). Of the patients 99% (90 of 91) underwent ileal diversion. Complications of any grade within 90 days occurred in 69% (63 of 91) of patients and 16% (15 of 91) experienced major complications within 90 days. Of the patients 21% (19 of 91) required hospital readmission within 90 days. The 90-day mortality rate was 2.2% (2 of 91). Significant cardiovascular/hematological complications (pulmonary embolism, myocardial infarction, deep vein thrombosis, transfusion) within 90 days were more common in the immediate than in the delayed cystectomy group (37% vs 15%, p = 0.02). Tissue healing complications (fascial dehiscence, wound infection, ureteral stricture, anastomotic stricture, stoma/loop revisions) were more common in the delayed than in the immediate cystectomy group (35% vs 12%, p = 0.05).
CONCLUSIONS: Salvage cystectomy is associated with acceptable morbidity, although complication rates are slightly higher than for other cystectomy series. Immediate cystectomies have more cardiovascular/hematological complications while delayed cystectomies have more tissue healing complications.
Copyright © 2012 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22177159     DOI: 10.1016/j.juro.2011.09.159

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  19 in total

1.  Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.

Authors:  Raymond H Mak; Daniel Hunt; William U Shipley; Jason A Efstathiou; William J Tester; Michael P Hagan; Donald S Kaufman; Niall M Heney; Anthony L Zietman
Journal:  J Clin Oncol       Date:  2014-11-03       Impact factor: 44.544

Review 2.  Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy.

Authors:  Adnan El-Achkar; Luis Souhami; Wassim Kassouf
Journal:  Curr Urol Rep       Date:  2018-11-03       Impact factor: 3.092

3.  The challenge of matching assays to biology in DNA damage response biomarkers for response to radiotherapy in bladder cancer.

Authors:  Neil B Desai; Aditya Bagrodia
Journal:  Transl Androl Urol       Date:  2019-12

4.  Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Canadian cost-effectiveness analysis.

Authors:  Ronald Kool; Ivan Yanev; Tarek Hijal; Marie Vanhuyse; Fabio L Cury; Luis Souhami; Wassim Kassouf; Alice Dragomir
Journal:  Can Urol Assoc J       Date:  2022-06       Impact factor: 2.052

5.  Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model.

Authors:  Diana Magee; Douglas Cheung; Amanda Hird; Srikala S Sridhar; Charles Catton; Peter Chung; Alejandro Berlin; Padraig Warde; Alexandre Zlotta; Neil Fleshner; Girish S Kulkarni
Journal:  Can Urol Assoc J       Date:  2022-04       Impact factor: 2.052

Review 6.  Trimodality therapy for bladder conservation in treatment of invasive bladder cancer.

Authors:  Timur Mitin; William U Shipley; Jason A Efstathiou; Niall M Heney; Donald S Kaufman; Richard J Lee; Anthony L Zietman
Journal:  Curr Urol Rep       Date:  2013-04       Impact factor: 3.092

Review 7.  Current Landscape and Future Directions on Bladder Sparing Approaches to Muscle-Invasive Bladder Cancer.

Authors:  James R Broughman; Winston Vuong; Omar Y Mian
Journal:  Curr Treat Options Oncol       Date:  2020-11-23

Review 8.  Role of prehabilitation following major uro-oncologic surgery: a narrative review.

Authors:  Enrico Maria Minnella; Francesco Carli; Wassim Kassouf
Journal:  World J Urol       Date:  2020-10-31       Impact factor: 3.661

9.  Risk of in-hospital complications after radical cystectomy for urinary bladder carcinoma: population-based follow-up study of 7608 patients.

Authors:  Mieke van Hemelrijck; Andreas Thorstenson; Philip Smith; Jan Adolfsson; Olof Akre
Journal:  BJU Int       Date:  2013-07-26       Impact factor: 5.588

10.  Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis.

Authors:  Victor M Schuettfort; Benjamin Pradere; Fahad Quhal; Hadi Mostafaei; Ekaterina Laukhtina; Keiichiro Mori; Reza Sari Motlagh; Margit Fisch; David D'Andrea; Michael Rink; Paolo Gontero; Francesco Soria; Shahrokh F Shariat
Journal:  World J Urol       Date:  2020-09-29       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.